» Articles » PMID: 35953863

Mechanisms of Chemotherapeutic Resistance and the Application of Targeted Nanoparticles for Enhanced Chemotherapy in Colorectal Cancer

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2022 Aug 11
PMID 35953863
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is considered one of the major malignancies that threaten the lives and health of people around the world. Patients with CRC are prone to post-operative local recurrence or metastasis, and some patients are advanced at the time of diagnosis and have no chance for complete surgical resection. These factors make chemotherapy an indispensable and important tool in treating CRC. However, the complex composition of the tumor microenvironment and the interaction of cellular and interstitial components constitute a tumor tissue with high cell density, dense extracellular matrix, and high osmotic pressure, inevitably preventing chemotherapeutic drugs from entering and acting on tumor cells. As a result, a novel drug carrier system with targeted nanoparticles has been applied to tumor therapy. It can change the physicochemical properties of drugs, facilitate the crossing of drug molecules through physiological and pathological tissue barriers, and increase the local concentration of nanomedicines at lesion sites. In addition to improving drug efficacy, targeted nanoparticles also reduce side effects, enabling safer and more effective disease diagnosis and treatment and improving bioavailability. In this review, we discuss the mechanisms by which infiltrating cells and other stromal components of the tumor microenvironment comprise barriers to chemotherapy in colorectal cancer. The research and application of targeted nanoparticles in CRC treatment are also classified.

Citing Articles

Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.

Alkatheeri A, Salih S, Kamil N, Alnuaimi S, Abuzar M, Abdelrahman S Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006069 PMC: 11859487. DOI: 10.3390/ph18020257.


Copper-based metal-organic frameworks for antitumor application.

Qian Y, Wang C, Xu R, Wang J, Chen Q, Zhu Z J Nanobiotechnology. 2025; 23(1):135.

PMID: 39987136 PMC: 11847370. DOI: 10.1186/s12951-025-03220-5.


The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.

Deli H, Vakili-Ghartavol Z, Asgari Y, Tavoosidana G, Eftekhar E, Ghahremani M BMC Cancer. 2025; 25(1):46.

PMID: 39789474 PMC: 11715296. DOI: 10.1186/s12885-024-13392-2.


An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer.

Shahzad M, Hameed H, Amjad A, Khan M, Qureshi I, Hameed A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39361171 DOI: 10.1007/s00210-024-03482-0.


Challenges in validation of combination treatment strategies for CRC using patient-derived organoids.

Benboubker V, Ramzy G, Jacobs S, Nowak-Sliwinska P J Exp Clin Cancer Res. 2024; 43(1):259.

PMID: 39261955 PMC: 11389238. DOI: 10.1186/s13046-024-03173-x.


References
1.
Druzhkova I, Shirmanova M, Ignatova N, Dudenkova V, Lukina M, Zagaynova E . Expression of EMT-Related Genes in Hybrid E/M Colorectal Cancer Cells Determines Fibroblast Activation and Collagen Remodeling. Int J Mol Sci. 2020; 21(21). PMC: 7662237. DOI: 10.3390/ijms21218119. View

2.
de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

3.
Tasdogan A, Ubellacker J, Morrison S . Redox Regulation in Cancer Cells during Metastasis. Cancer Discov. 2021; 11(11):2682-2692. PMC: 8563381. DOI: 10.1158/2159-8290.CD-21-0558. View

4.
Ma X, Chen J, Liu J, Xu B, Liang X, Yang X . IL-8/CXCR2 mediates tropism of human bone marrow-derived mesenchymal stem cells toward CD133 /CD44 Colon cancer stem cells. J Cell Physiol. 2020; 236(4):3114-3128. DOI: 10.1002/jcp.30080. View

5.
Sui H, Zhao J, Zhou L, Wen H, Deng W, Li C . Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer. Cancer Lett. 2017; 403:86-97. DOI: 10.1016/j.canlet.2017.05.013. View